0
0
NEW DELHI — As oncology enters a revolutionary era driven by precision medicine and targeted therapies, India faces a daunting paradox: cutting-edge science is advancing faster than the health system’s ability to deliver it to the people who need it most. At a high-level roundtable organized by the Indian Cancer Society in New Delhi this week, prominent oncologists, public health experts, and cancer survivors issued a urgent, unified call for a coordinated national strategy. The core message was clear: India must bridge the stark divide between scientific possibility and economic reality, shifting the focus from simply developing new drugs to ensuring they are affordable and accessible to all segments of society.
The discussion, timed alongside Cancer Survivor Month, arrived at a critical juncture for the nation’s public health infrastructure. With insurance coverage fragmented, specialized diagnostic facilities heavily concentrated in urban centers, and out-of-pocket healthcare expenses remaining a primary driver of household poverty, experts warned that isolated hospital-level decisions are no longer sufficient. Without a centralized, evidence-based framework, the benefits of modern oncology will remain restricted to a fraction of wealthy patients who can pay out of pocket.
The Rising Burden: Understanding India’s Cancer Landscape
The push for a cohesive national framework is driven by sobering epidemiological data. According to the International Agency for Research on Cancer’s (IARC) GLOBOCAN 2022 report, India recorded an estimated 1,413,316 new cancer cases and 916,827 cancer-related deaths in 2022 alone.
The data highlights distinct gender-based and site-specific patterns within the Indian population:
-
Overall & Women: Breast cancer remains the most frequently diagnosed malignancy nationwide, followed closely by cervical cancer.
-
Men: Lip and oral cavity cancers represent the highest burden, heavily driven by regional risk factors such as tobacco use.
These figures underscore the scale of the challenge. When advanced therapies carry price tags that exceed the average annual household income, a lack of access effectively converts a treatable diagnosis into a financial catastrophe or a terminal outcome.
Innovation vs. Affordability: A False Dichotomy
A central theme of the New Delhi roundtable was dismantling the long-held assumption that emerging markets must choose between providing innovative care or maintaining fiscal responsibility. Public health advocates argued that a middle path exists through aggressive, structured prioritization.
“We are entering an extraordinary era of scientific innovation,” noted Jyotsna Govil, chairperson of the Indian Cancer Society. “However, the true metric of our success is not the discovery of a molecule, but whether that advance actually reaches every single patient who can clinically benefit from it.”
To achieve this, experts are advocating for the institutionalization of Health Technology Assessment (HTA). HTA is a systematic, multi-disciplinary policy tool used by governments worldwide to evaluate the clinical effectiveness, potential harms, and long-term cost-effectiveness of medical technologies before allocating public funds. Rather than adopting every new, heavily marketed drug, HTA allows policymakers to compare novel interventions directly against existing standards of care to determine if the marginal survival gain justifies the public expense.
“Evidence-based prioritization and real-world data are our best tools,” explained Dr. Ravi Mehrotra, a management committee member of the Indian Cancer Society and former director of the National Institute of Cancer Prevention and Research (NICPR). “By assessing local data, we can ensure that scientific breakthroughs produce meaningful, quantifiable gains for the largest possible number of patients, rather than superficial benefits for a few.”
The Realities of Uneven Infrastructure
For the average patient in India, the barriers to care are multi-layered and persistent. Precision medicine relies heavily on advanced companion diagnostics—such as next-generation sequencing (NGS) and specific biomarker testing—to match a patient with a targeted therapy.
Currently, these diagnostic facilities, alongside dedicated tertiary oncology centers, are heavily concentrated in tier-1 metropolitan areas.
[Late or Inaccurate Diagnosis in Rural/Semi-Urban Areas]
│
▼
[Long-Distance Travel to Urban Tertiary Centers]
│
▼
[Financial Strain / Out-of-Pocket Expense for Advanced Therapy]
│
▼
[Treatment Discontinuation or Suboptimal Care Outcomes]
Dr. Ajay Gogia, Professor of Medical Oncology at the Dr. B.R.A. Institute Rotary Cancer Hospital, AIIMS New Delhi, emphasized that while precision medicine has transformed outcomes by pairing the right therapy with the right patient, its clinical utility is fundamentally undermined if the underlying system is inequitable. “An advanced drug is only effective if the patient can access the molecular testing required to prescribe it, and subsequently afford the treatment course without interrupting therapy,” Dr. Gogia stated.
Leveraging Public Financing: The Role of Ayushman Bharat
The debate over sustainable funding inevitably highlights India’s public safety nets, most notably the Pradhan Mantri Jan Arogya Yojana (Ayushman Bharat). The scheme has fundamentally shifted how tertiary care is financed for the bottom 40% of the population.
According to government data released by Union Health Minister J.P. Nadda, the program has supported more than 68 lakh (6.8 million) cancer treatments valued at over ₹13,000 crore since its inception in 2018. Crucially, a significant proportion of these treatments were delivered to patients residing in rural areas, confirming that the infrastructure is successfully reaching historically underserved populations.
However, the rapid evolution of oncology creates a moving target for public insurance. Incorporating newer immunotherapies or targeted biologics into the Ayushman Bharat benefit packages without strict gatekeeping could quickly deplete limited resources.
Participants at the roundtable suggested a phased approach: utilizing robust scientific evaluation frameworks to gradually introduce proven, high-impact innovations into public programs. This strategy aims to systematically lower out-of-pocket expenditures while preventing the destabilization of public healthcare budgets.
Policy Implications and the Local Data Gap
For health policymakers, the consensus from New Delhi indicates that temporary subsidies or sporadic price-control mandates on drugs are insufficient band-aids. A sustainable strategy requires holistic investment: upgrading regional diagnostic infrastructure, establishing clear standardized referral pathways, and expanding evidence-based public reimbursement models.
Furthermore, experts highlighted a significant structural limitation: the national data gap. While India’s National Cancer Registry Programme (NCRP) provides vital baseline estimates, comprehensive tracking across the diverse nation remains uneven. Many current policy decisions rely on a combination of registry data and statistical modeling.
Dr. (Prof) Jyoti Wadhwa of Apollo Hospital, Delhi, noted that India’s vast and genetically diverse patient population provides a unique foundation for robust clinical research. “We possess the clinical expertise and the patient volume to be a global leader in oncology research,” Dr. Wadhwa stated. “What we urgently need is stronger collaborative research infrastructure to generate local, real-world evidence that accurately reflects Indian realities and disease patterns.”
As drug pricing structures, clinical trial data, and regional epidemiological trends evolve, any national strategy will require regular, iterative updates driven by high-quality local data.
The Practical Bottom Line for Families
For patients, survivors, and caregivers navigating a complex diagnosis, this systemic shift offers an important perspective. The takeaway is not that every newly approved global therapy must be pursued regardless of cost or financial ruin. Many highly publicized, expensive therapies offer only incremental extensions of survival in specific advanced stages, rather than definitive cures.
Instead, treatment choices must be balanced against clinical evidence, realistic quality-of-life goals, and individual financial stability. Public health experts emphasize that until a national delivery strategy is fully realized, early detection through routine screening and immediate navigation into the formal healthcare system remain a patient’s most powerful defense—long before the financial costs of advanced care become the primary barrier.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Roundtable Source: India needs national strategy to improve access to new cancer therapies: Experts. Times of India. Published July 2, 2026. (Reporting on the Indian Cancer Society expert panel proceedings, New Delhi).
